SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-028739
Filing Date
2023-08-15
Accepted
2023-08-14 19:43:49
Documents
108
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form20-f.htm   iXBRL 20-F 2319624
2 ex12-1.htm EX-12.1 10806
3 ex12-2.htm EX-12.2 10703
4 ex13-1.htm EX-13.1 4474
5 ex13-2.htm EX-13.2 4519
6 ex15-1.htm EX-15.1 6789
7 ex15-2.htm EX-15.2 4189
8 ex16-1.htm EX-16.1 8778
9 image_002.jpg GRAPHIC 64158
10 image_003.jpg GRAPHIC 61655
11 exlogo.jpg GRAPHIC 7064
12 ex15-2_001.jpg GRAPHIC 3058
  Complete submission text file 0001493152-23-028739.txt   8609724

Data Files

Seq Description Document Type Size
13 XBRL SCHEMA FILE okyo-20230331.xsd EX-101.SCH 86738
14 XBRL CALCULATION FILE okyo-20230331_cal.xml EX-101.CAL 62172
15 XBRL DEFINITION FILE okyo-20230331_def.xml EX-101.DEF 215975
16 XBRL LABEL FILE okyo-20230331_lab.xml EX-101.LAB 455106
17 XBRL PRESENTATION FILE okyo-20230331_pre.xml EX-101.PRE 348172
102 EXTRACTED XBRL INSTANCE DOCUMENT form20-f_htm.xml XML 1409960
Mailing Address 55 PARK LANE LONDON X0 W1K 1NA
Business Address 55 PARK LANE LONDON X0 W1K 1NA 44 (0) 207 495 2379
OKYO Pharma Ltd (Filer) CIK: 0001849296 (see all company filings)

IRS No.: 000000000
Type: 20-F | Act: 34 | File No.: 001-41386 | Film No.: 231172843
SIC: 2836 Biological Products, (No Diagnostic Substances)